Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 751 - 775 of 857 in total
The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec City, Canada. The vaccine was developed by creating SARS-Cov-2 virus-like particles (CoVLPs), which mimic the structure of the virus without carrying the genetic components required for infection. VLPs are thought to have multiple mechanisms involving the...
Investigational
Matched Description: … A Phase 1 clinical trial was launched in July 2020 evaluating the safety, tolerability, and immunogenicity ... In July 2020, Medicago partnered with Dynavax to test the vaccine with its adjuvant, Cpg 1018 (also known ... The Coronavirus-Like Particle COVID-19 Vaccine is in development and testing through Meidcago in Quebec …
The V591 vaccine, part of Merck’s COVID-19 vaccine programming, was developed using a modified measles vaccine virus as a vector for COVID-19 antigen delivery . Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge and accelerate the development of V591 to phase I...
Investigational
Matched Description: … and accelerate the development of V591 to phase I clinical trials (NCT04498247)[L30593]. ... Through Merck’s acquisition of Thermis in May 2020, they were able to leverage Thermis’ platform knowledge …
Viagenpumatucel-L is under investigation in clinical trial NCT02117024 (A Phase 2 Study of Viagenpumatucel-l (HS-110) in Patients With Non-small Cell Lung Cancer).
Investigational
Matched Synonyms: … Gp96-igg1-fc fusion protein and hla-a1 expressing, irradiated ad-100 whole cell vaccine …
TN-401 is a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type human PKP2 gene.
Investigational
Matched Synonyms: … A native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and the wild-type …
Matched Description: … TN-401 is a native AAV9 capsid with a genomic cassette containing a cardiomyocyte-specific promoter and
VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein.
Investigational
Matched Synonyms: … allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking …
Matched Description: … VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy …
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence ... and replication, to initiate subsequent immune responses in the body. ... The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration …
The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program. Similar to BNT162b2, BNT162b3 uses a nucleoside-modified RNA (modRNA) technology. Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate further testing of it. As such, BNT162b3 has...
Investigational
Matched Description: … As such, BNT162b3 has entered a phase I/II study in early September 2020 (NCT04537949). ... Pfizer and BioNTech deemed this compound as promising in preclinical trials and have decided to initiate ... The BNT162b3 vaccine is the latest addition to BioNTech and partner Pfizer’s mRNA COVID-19 vaccine program …
MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. Medigen has combined forces with Dynavax, which offers an advanced adjuvant, CpG 1018 (also known as ISS-1018), for use with its vaccine. As of...
Investigational
Matched Description: … As of September 2020, the vaccine candidate is in Phase 1 clinical trials to assess its safety and immunogenicity ... MVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation …
Atacicept is a recombinant fusion protein combined with the extracellular ligand binding portion of TACI.
Investigational
Matched Synonyms: … Human Transmembrane Activator and CAML Interactor (TACI) Immunoglobulin G1 Fc Domain Fusion Protein ( …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Investigational
Matched Synonyms: … interfering RNA (siRNA) therapeutic directed against transforming growth factor-beta 1 (TGF-beta 1) and
Investigational
Matched Synonyms: … homopolymer, complex with 5'-inosinic acid homopolymer (1:1), compd. with cellulose carboxymethyl ether and ... L-lysine, homopolymer, compd. with cellulose carboxymethyl ether and 5'-inosinic acid homopolymer complex ... homopolymer, complex with 5'-cytidylic acid homopolymer (1:1), compd. with cellulose carboxymethyl ether and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Investigational
Matched Synonyms: … engager antibody with a single chain fc moiety that binds to b cell maturation antigen surface receptor and
Ergidina is a recombinant human minibody against complement component C5 fused with RGD-motif.
Investigational
Matched Synonyms: … Neutralizing scFv dimer to C5 fused at the C terminal end to the Fc domains of human IgG1 and the cyclic …
The CVnCov Vaccine (or CV07050101) is in development by CureVac AG. The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration and replication, to initiate subsequent immune responses in the body. As of June 2020, the company received regulatory approval from German and Belgian Authorities...
Investigational
Matched Description: … As of June 2020, the company received regulatory approval from German and Belgian Authorities to commence ... and replication, to initiate subsequent immune responses in the body. ... The vaccine uses mRNA technology to create a protein associated with SARS-CoV2, and upon administration …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Investigational
Matched Synonyms: … ALLOGENEIC UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC STEM AND PROGENITOR CELLS MGTA-456 ... Allogeneic umbilical cord blood (UCB) cell therapy product consisting of two cell fractions (CD34 enriched and
Experimental
Matched Name: … Hybrid Between B and C Type Hemes (Protoporphyrin Ixcontaining Fe) …
Matched Iupac: … 3-[20-(2-carboxyethyl)-15-ethenyl-10-ethyl-5,9,14,19-tetramethyl-2,22,23,25-tetraaza-1-ferraoctacyclo …
The SARS-CoV-2 Inactivated Vaccine is a purified vaccine that contains multiple antigens from the virus and is inactivated in Vero Cells . This vaccine specifically was developed in collaboration with the Chinese Academy of Medical Sciences, West China Second University Hospital, and Yunan Center for Disease Control and Prevention. As...
Investigational
Matched Description: … As of June, 2020, safety and Immunogenicity trials are currently underway for this vaccine (NCT04470609 ... Yunan Center for Disease Control and Prevention. ... SARS-CoV-2 Inactivated Vaccine is a purified vaccine that contains multiple antigens from the virus and
The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and effectiveness against SARS-CoV-2-induced pneumonia. With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the recombinant chimeric DC vaccine reduces the risk of virulence recovery, pre-existing anti-vector immunity, and incomplete viral inactivation. As...
Investigational
Matched Description: … As of August 2020, this vaccine is being tested for prophylaxis against COVID-19 in human clinical trials ... With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the ... The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and
AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. The candidate is a plasmid DNA vaccine developed using an intradermal gene transfer method targeting the SARS-CoV-2 spike protein. The gene transfer method increases the efficiency of gene expression and antibody production capability, garnering a more efficient DNA...
Investigational
Matched Description: … On September 8, 2020 AnGes announced collaboration with Brickell Biotech, Inc. following completion of ... AG0301-COVID19 is a vaccine candidate developed by AnGes Inc. and Osaka University. ... The gene transfer method increases the efficiency of gene expression and antibody production capability …
Investigational
Matched Synonyms: … Flt3 ligand, IL-7, IL-15 and IL-2 to generate the NK cell ... The cells are expanded and differentiated in the presence of cytokines including thrombopoietin, SCF, …
Tavokinogene telseplasmid consists of a DNA Plasmid Vector Encoding IL-12.
Investigational
Matched Synonyms: … Dna plasmid containing genes coding for the human interleukin 12 (il-12) p35 and p40 subunits that are ... separated by an internal ribosomal entry site (ires) and under the control of a single cytomegalovirus …
LNP-nCoVsaRNA is a purified, synthetic mRNA vaccine candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and invade human cells. The vaccine was developed in and tested by the Medical Research Council Clinical Trials Unit at UCL in the UK, and jointly...
Investigational
Matched Description: … As of July 2020, a clinical trial (COVAC1) is underway (ISRCTN17072692) to test the safety and immunogenicity ... the UK, and jointly funded by UK Research and Innovation. ... candidate encoding the S glycoprotein of SARS-CoV-2, which is used primarily by the virus to attach to and
Investigational
Matched Synonyms: … specific T lymphocytes targeting BK virus, cytomegalovirus, human herpes virus-6, Epstein Barr virus, and
Investigational
Matched Synonyms: … Fc-fusion protein comprised of an anti-CXCR4 i-body tethered at its C-terminus to constant domains 2 and
Sabestomig is under investigation in clinical trial NCT05216835 (Safety and Preliminary Efficacy Assessment of AZD7789 in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma).
Investigational
Matched Synonyms: … 3, TIM3, TIM-3, TIMD3, CD366)], humanized and Ho ... HAVCR2 (hepatitis A virus cellular receptor 2, T cell immunoglobulin and mucin domains family member ... Immunoglobulin G1-kappa/lambda, anti-[Homo sapiens PDCD1 (programmed cell death 1, PD1, PD-1, CD279) and
Matched Description: … Sabestomig is under investigation in clinical trial NCT05216835 (Safety and Preliminary Efficacy Assessment …
Displaying drugs 751 - 775 of 857 in total